Lv12
30 积分 2022-04-24 加入
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
58分钟前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
1小时前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
1小时前
已完结
Contemporary CMML Risk Stratification and Management
3天前
已完结
Chronic myelomonocytic leukaemia
3天前
已完结
Recent developments in myeloid immune modulation in cancer therapy
23天前
已完结
Recent developments in myeloid immune modulation in cancer therapy
23天前
已完结
Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial
3个月前
已完结
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
3个月前
已完结
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
3个月前
已关闭
皖公网安备34019202002308
